Cellectis S A : Corporate Presentation - June 2021

COMMITMENT TO A CURE

Investor Presentation

June 2021

cellectis.com

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "at this time," "anticipate," "believe," "expect," "on track," "plan," "scheduled," and "will," or the negative of these and similar expressions.

These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management, include statements about our research and development projects and priorities, our pre-clinical project development efforts, the timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data, the adequacy of our supply of clinical vials, the timing of completion of construction of our Raleigh, North Carolina manufacturing facility, and

operational capabilities at our manufacturing facilities, and the sufficiency of cash to fund operations.

These forward-looking statements are made in light of
information currently available to us and are subject to
numerous risks and uncertainties, including with respect to
the numerous risks associated with biopharmaceutical
product candidate development as well as the duration
and severity of the COVID-19 pandemic and governmental
and regulatory measures implemented in response to the
evolving situation.
With respect to our cash runway, our operating plans,
including product development plans, may change as a
result of various factors, including factors currently
unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form
20-F and the financial report (including the management
report) for the year ended December 31, 2020 and
subsequent filings Cellectis makes with the Securities
Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our
actual results, performance or achievements to be
materially different from those expressed or implied by the
forward-looking statements. Except as required by law, we
assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual
results could differ materially from those anticipated in the
forward-looking statements, even if new information	P2
becomes available in the future.

WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS

21 years	9 years	8 clinical trials
of expertise in	of experience in allogeneic	ongoing as of 2021;
gene editing	CAR-T manufacturing	3 Cellectis-sponsored
		7 partnered

INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS

In 2012 . .

Mission to develop allogeneic CAR T-cells begins

In 2015 . .

First-in-man compassionate use of an allogeneic CAR-T product candidate occurs

P3

ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T

Autologous process:		Manufacturing variability + several weeks before treatment is available

1.	2.	3.	4.
CANCER TREATMENT	CANCER	MANUFACTURING OF A	INDIVIDUAL CAR-T
DECISION	PATIENT APHERESIS	SINGLE PATIENT	THERAPY
		PRODUCT

Allogeneic process:

		Consistent manufacturing + quality		Immediate treatment

HEALTHY DONOR	SCALABLE	MASS PRODUCED	1.	2.
APHERESIS	MANUFACTURING	ALLOGENEIC CAR-T	CANCER TREATMENT	OFF-THE-SHELF
	OF 100+ DOSES/BATCH	THERAPIES	DECISION	CAR-T THERAPY

• TIME SAVED
• COST EFFECTIVE
• MARKET ACCESS

P4

UCARTs - ALLOGENEIC CAR T-CELLS THROUGH PRECISION GENE EDITING

R A T I O N A L

Engineering

via accurate insertion of best CAR

UCART

Universal Chimeric

Antigen Receptor T-cell

SAFE

Administration

Avoid GvHD via knock-out of T-Cell Receptor (TCR)

E F F E C T I V E

Persistence

via knock-out of CD52 or β2-microglobulin

TUMOR CELL

S M A R T

Action

CAR linked to suicide switch and

other cell engineering features (e.g. PD-1 KO)

P5